Tomson Bianjian announced on the evening of December 25 that the company signed the "Guangfa Shunde Health Industry Investment Fund (Phase I) (Limited Partnership) with Guangfa Shunde Investment Management Co., Ltd. and Guangfa Shunde Zhisheng Investment Management Co., Ltd. on December 25. Partnership Agreement. Tomson Bianjian decided to invest 60 million yuan in his own funds to become the Guangfa Shunde Health Industry Investment Fund (Phase I). It is expected that after the fund raising is completed, Tomson Bianjian will account for 60% of the total fund contribution.
The operating period of five years fixed term, two-year period may be extended, scope of business: health management areas (mainly mobile health care, a large field of medical data, molecular diagnostics, rehabilitation and medical segments) or debt investments and equity investments permitted by law Other investment activities, financial advisory services related to equity investment and debt investment.
According to the announcement, GF-Shengde Health Industry Investment Fund focuses on new technologies in health management (such as molecular diagnosis), new trends (such as rehabilitation medicine, medical big data) and new formats (such as mobile medical, medical e-commerce). In addition, the fund may also invest in cross-cutting areas such as customized health products, customized rehabilitation programs, CRO (Contract Research Organization), and food safety inspection.
In fact, Tomson, a leading health care company, has always wanted to do more in the health care field. The industry believes that this time together with the fund company to set up an industrial investment fund, intends to deploy a large health industry through early investment, PE investment, and mature into the listed company. If it is not possible to acquire, it can also establish a close business relationship with it, expand its resource advantages and platform advantages, and provide incentives for the company to improve its industrial chain and achieve greater performance.
Ningxia Eppen Biotec CO.,LTD , https://www.nxeppen.com